Zobrazeno 1 - 10
of 295
pro vyhledávání: ''
Autor:
Jennifer Caplain, Madhumita Das, Elizabeth Grimm, Shrikar Rajagopal, Oksana B. Serebrennikova, Robert E. Martell, Philip N. Tsichlis, Mohammad Wasif Saif
Publikováno v:
Cancer Chemotherapy and Pharmacology. 84:1323-1331
Metformin activates AMP-related pathways leading to inactivation of mammalian target of rapamycin (mTOR) and suppression of its downstream effectors, crucial for cancer growth. Epidemiologic studies showed a reduced incidence and improved survival in
Autor:
Daniel B Huang, Jun Kawashima, Karen L. Reckamp, Sukhmani K. Padda, Joel W. Neal, Shengchun Kong, Mark Kowalski, Marianna Koczywas, Heather A. Wakelee
Publikováno v:
Cancer Chemotherapy and Pharmacology
Introduction Preclinical evidence suggests the feedforward cytokine loop of interleukin-6/Janus kinases (JAK)/STAT3 plays a role in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistance in EGFR-mutated non-small cell lung c
Autor:
Tomohiro Uto, Takafumi Suda, Shun Matsuura, Kazuhiro Asada, K. Tanaka, Naoki Inui, Tomoyuki Fujisawa, Noriyuki Enomoto, Hideki Yasui, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Hideki Kusagaya, Dai Hashimoto, Takashi Matsui, Yutaro Nakamura, Hironao Hozumi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 84:147-153
There remains an unmet clinical need for the control of chemotherapy-induced nausea and vomiting (CINV), particularly in the prevention of nausea and the delayed phase control. We evaluated the efficacy and safety of antiemetic therapy with olanzapin
Autor:
Campone, F, Bachelot, F, Penault-Llorca, F., Pallis, F, Agrapart, F, Pierrat, F, Poirot, F., Dubois, F., Xuereb, F, Bossard, F., Guigal-Stephan, F, Lockhart, F, Andre, F., Campone, M., Bachelot, Thomas, Pallis, A., Agrapart, Vincent, Pierrat, M., Poirot, C., Xuereb, L., Bossard, C., Guigal-Stephan, N., Lockhart, B.
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2019, 83 (4), pp.743-753. ⟨10.1007/s00280-018-03765-3⟩
Cancer Chemotherapy and Pharmacology, 2019, 83 (4), pp.743-753. ⟨10.1007/s00280-018-03765-3⟩
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2019, 83 (4), pp.743-753. ⟨10.1007/s00280-018-03765-3⟩
Cancer Chemotherapy and Pharmacology, 2019, 83 (4), pp.743-753. ⟨10.1007/s00280-018-03765-3⟩
The primary objective of this multicentric dose allocation and dose expansion study was to determine the MTD and the DLTs of the lucitanib (a tyrosine kinase inhibitor of the FGFR/VEGFR/PDFGR pathways)/fulvestrant combination. Postmenopausal women wi
Autor:
Stephan Krähenbühl, Sabine Schmid, Alessandra Curioni-Fontecedro, Sacha I. Rothschild, Martin Früh, Anne Schett, Markus Joerger, Christoph Driessen
Publikováno v:
Cancer chemotherapy and pharmacology. 85(1)
In this study, we test the hypothesis that the use of ATB reduces the efficacy of PD(L)1-targeting mAb. We included patients with locally advanced, inoperable or metastatic, EGFR wildtype and ALK-negative non-small-cell lung cancer (NSCLC) who receiv
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose An integrated population pharmacokinetic (popPK) model was developed to describe the pharmacokinetics (PK) of tyrosine kinase inhibitor cabozantinib in healthy volunteers (HVs) and patients with various cancer types and to identify any differ
Autor:
Ryosuke Chiba, Junya Sato, Satoshi Moriguchi, Kohei Yamauchi, Kenzo Kudo, Naoto Morikawa, Heisuke Saito, Satoru Nihei
Publikováno v:
Cancer Chemotherapy and Pharmacology. 80:545-553
Afatinib maleate (AFA) is a second-generation, tyrosine kinase inhibitor (TKI) treatment for specific variants of non-small cell lung cancer exhibiting epidermal growth factor receptor (EGFR) mutations. In this study, we measured the blood AFA levels
Autor:
Mio Takeuchi, Masayuki Miyazaki, Kiyofumi Yamada, Yukihiro Noda, Hiroshi Kato, Miho Asai, Momokazu Gotoh, Naoto Sassa, Akane Iwai
Publikováno v:
Cancer Chemotherapy and Pharmacology. 78:855-862
Axitinib is a selective tyrosine kinase inhibitor of VEGF receptors, approved for advanced renal cell carcinoma (RCC). Associations between axitinib plasma exposure, genetic polymorphisms of ABC transporters and axitinib-induced toxicities have not b
Autor:
Yuji Kiuchi, Mariko Iwase, Natsumi Seba, Yuki Nishimura, Hiroo Ishida, Yusuke Masuo, Ken-ichi Fujita, Yukio Kato
Publikováno v:
Cancer chemotherapy and pharmacology. 83(5)
Pazopanib is an orally active, multi-targeted tyrosine kinase inhibitor. A previous phase I study demonstrated that coadministration of pazopanib with irinotecan increases the area under the plasma concentration–time curve (AUC) for SN-38, an activ
Autor:
Hao Peng, Hao Hu, Hua-Lin Cai, Lin Guo, Jin-an Ma, Kai-Lin Que, Feng Wang, Ying Zhang, Chen Han, Dan Tang, Miao Yan, Jia Liu
Publikováno v:
Cancer chemotherapy and pharmacology. 83(4)
To compare efficacy and safety of postponing administration of aprepitant and routine triple-antiemetic treatment for chemotherapy-induced nausea and vomiting in patients who received docetaxel and cisplatin multi-day chemotherapy treatment, and to e